A carregar...
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet...
Na minha lista:
| Publicado no: | J Blood Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602457/ https://ncbi.nlm.nih.gov/pubmed/28979172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S121550 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|